I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

WCLC 2019

World Conference on Lung Cancer 2019

The annual WCLC meeting brings together the world’s largest gathering of lung cancer professionals.

 

Boehringer Ingelheim is dedicated to collaborating with the oncology community on a shared journey to deliver leading science. We will be holding a symposium on treatment sequencing for advanced non-small cell lung cancer (NSCLC), as well as presenting data highlighting recent findings in the treatment of lung cancer. Please see below for further details.

 

For more information on WCLC 2019, click here.

Booth #307
1 Symposium
6 Publications
View Expo Plan
7-10 September 2019
Fira Gran Via, Barcelona, Spain
Treatment sequencing for advanced non–small cell lung cancer
symposium_cal
8 September 2019
symposium_cal
18:00pm - 19:30pm
symposium_cal
Hall 8.0, Room: Hilton Head (1978)

Join us at our WCLC symposium to hear an international faculty of experts discuss first-line treatment decisions for EGFR mutation-positive NSCLC, and second-line treatment decisions for advanced NSCLC, including squamous cell carcinoma and non-mutated, non-squamous disease.

        Tetsuya Mitsudomi, Kindai University

Tetsuya Mitsudomi, Kindai University

Chair; Moderator of Q&A sessions
        Keunchil Park, Sungkyunkwan University School of Medicine

Keunchil Park, Sungkyunkwan University School of Medicine

Maximising time on EGFR TKI therapy

        Martin Schuler, Essen University Hospital

Martin Schuler, Essen University Hospital

Uncommon but not unknown: efficacy of EGFR TKIs for uncommon mutations

        David Gandara, University of California

David Gandara, University of California

The role of EGFR TKIs in the treatment of squamous NSCLC
        Nick Pavlakis, University of Sydney

Nick Pavlakis, University of Sydney

NSCLC: the role of anti-angiogenic therapy in overcoming resistance to immunotherapy

Publications

Come and find out more about our emerging data during the scientific programme at WCLC.

Please revisit this page for further details about our poster presentations nearer the time of the congress.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types
Publications
A Phase IIIb open-label study of afatinib* in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: Final analysis
TBC
TBC
TBC
Presenter(s): Wu et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: TBC
Afatinib in EGFR mutation-positive NSCLC: activity in patients with brain metastases, and impact on CNS progression/spread
TBC
TBC
TBC
Presenter(s): O’Byrne et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: TBC
Targeting NRG1-fusions in lung adenocarcinoma: afatinib as a novel potential treatment strategy
TBC
TBC
TBC
Presenter(s): Duruisseaux et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: TBC
Afatinib in EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: experience in ‘real-world’ clinical practice
TBC
TBC
TBC
Presenter(s): Brückl et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: TBC
Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: combined analysis of two single-arm Phase IIIb studies
TBC
TBC
TBC
Presenter(s): De Marinis et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: TBC
A Phase IIIb, open-label study of afatinib in Caucasian EGFR TKI-naïve patients with EGFRm+ NSCLC: an interim analysis
TBC
TBC
TBC
Presenter(s): De Marinis et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: TBC
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: July 2019